8-K filed Sep 9, 2026 at 08:33 ET
Xeris Biopharma hosted a program overview webinar detailing its comprehensive development plan for XP-8121, an investigational once-weekly subcutaneous levothyroxine for hypothyroidism. The company confirmed the Phase 3 Cornerstone registrational study is on track to initiate by year-end 2026 with topline data expected in late 2028, and potential FDA approval and launch anticipated in 2030. Management guided for XP-8121 peak net revenue potential of $1 billion to $3 billion, but this filing contains no actual financial results or new clinical data, it is a forward-looking pipeline update.